157 related articles for article (PubMed ID: 32609585)
1. Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation.
Kouzy R; Abi Jaoude J; Lin D; El Alam MB; Minsky BD; Koay EJ; Das P; Holliday EB; Klopp AH; Colbert LE; Taniguchi CM
JCO Oncol Pract; 2020 Dec; 16(12):e1524-e1531. PubMed ID: 32609585
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
3. Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
Ludmir EB; Kachnic LA; Czito BG
Surg Oncol Clin N Am; 2017 Jan; 26(1):91-113. PubMed ID: 27889040
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
5. Definitive chemoradiotherapy for anal canal cancer: single-center experience.
Tachibana I; Nishimura Y; Inada M; Fukuda K; Ishikawa K; Nishikawa T; Yokokawa M; Nakamatsu K; Kanamori S; Hida JI
Int J Clin Oncol; 2018 Dec; 23(6):1121-1126. PubMed ID: 29992389
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
7. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
Goodman KA; Julie D; Cercek A; Cambridge L; Woo KM; Zhang Z; Wu AJ; Reidy DL; Segal NH; Stadler ZK; Saltz LB
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1087-1095. PubMed ID: 28721892
[TBL] [Abstract][Full Text] [Related]
10. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
Salama JK; Mell LK; Schomas DA; Miller RC; Devisetty K; Jani AB; Mundt AJ; Roeske JC; Liauw SL; Chmura SJ
J Clin Oncol; 2007 Oct; 25(29):4581-6. PubMed ID: 17925552
[TBL] [Abstract][Full Text] [Related]
12. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Ajani JA; Winter KA; Gunderson LL; Pedersen J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett C
JAMA; 2008 Apr; 299(16):1914-21. PubMed ID: 18430910
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
[TBL] [Abstract][Full Text] [Related]
15. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
16. Combined chemoradiation therapy for anal cancer. A report of 56 cases.
Doci R; Zucali R; Bombelli L; Montalto F; Lamonica G
Ann Surg; 1992 Feb; 215(2):150-6. PubMed ID: 1546901
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy for anal cancer.
Tom A; Bennett AV; Rothenstein D; Law E; Goodman KA
Qual Life Res; 2018 Jan; 27(1):97-103. PubMed ID: 28884454
[TBL] [Abstract][Full Text] [Related]
18. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
[TBL] [Abstract][Full Text] [Related]
19. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).
Feliu J; Garcia-Carbonero R; Capdevila J; Guasch I; Alonso-Orduna V; Lopez C; Garcia-Alfonso P; Castanon C; Sevilla I; Cerezo L; Conill C; Quintana-Angel B; Sanchez ME; Ghanem I; Martin-Richard M; Lopez-Gomez M; Leon A; Caro M; Fernandez T; Maurel J
Cancer Med; 2020 Feb; 9(3):1008-1016. PubMed ID: 31851776
[TBL] [Abstract][Full Text] [Related]
20. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]